Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01992861 · ClinicalTrials.gov registry record
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
A clinical trial, sponsored by University of Washington.
- Terminated
- Registry status
- 51
- Enrollment target
NCT01992861: Clinical Trial study, sponsored by University of Washington.
NCT01992861 is a clinical trial that was terminated before completion, run by University of Washington. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01992861 was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. PET is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Comparing results of diagnostic procedures, such as MRI and PET, done before, during and after radiation and chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
- RADIATION Fludeoxyglucose F-18
- PROCEDURE Diffusion Weighted Imaging
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-02-14 |
| Est. Completion | 2022-01 |
Why NCT01992861 stopped before completion
NCT01992861 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Computed Tomography is the first listed.
NCT01992861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01992861 about?
NCT01992861 is a clinical study titled "MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer". This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures o...
What is the current status of trial NCT01992861?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2014-02-14. Estimated completion is 2022-01.
What interventions are being tested in trial NCT01992861?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Spectroscopic Imaging (PROCEDURE), Fludeoxyglucose F-18 (RADIATION), Diffusion Weighted Imaging (PROCEDURE), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT01992861?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI